AAPL 209.68 -3.3644% MSFT 378.77 -1.1741% NVDA 115.58 -0.1382% GOOGL 162.76 -2.6031% GOOG 164.73 -2.5266% AMZN 193.89 -2.514% META 590.64 -4.6678% AVGO 191.36 -1.4776% LLY 801.65 -2.4591% TSLA 240.68 -2.9868% TSM 171.59 -3.1495% V 328.55 -1.2889% JPM 225.19 -1.1891% UNH 481.52 0.0852% NVO 75.89 1.4708% WMT 84.5 -0.8216% LVMUY 129.76 -2.7942% XOM 108.67 -0.4215% LVMHF 655.0 -2.0693% MA 519.83 -0.9168%
AAPL 209.68 -3.3644% MSFT 378.77 -1.1741% NVDA 115.58 -0.1382% GOOGL 162.76 -2.6031% GOOG 164.73 -2.5266% AMZN 193.89 -2.514% META 590.64 -4.6678% AVGO 191.36 -1.4776% LLY 801.65 -2.4591% TSLA 240.68 -2.9868% TSM 171.59 -3.1495% V 328.55 -1.2889% JPM 225.19 -1.1891% UNH 481.52 0.0852% NVO 75.89 1.4708% WMT 84.5 -0.8216% LVMUY 129.76 -2.7942% XOM 108.67 -0.4215% LVMHF 655.0 -2.0693% MA 519.83 -0.9168%

small-cap

Watch Out for One NASDAQ - Listed Bio Pharmaceuticals Stock– Mind Medicine (MindMed) Inc

Feb 05, 2025 | Team Kalkine
Watch Out for One NASDAQ - Listed Bio Pharmaceuticals Stock– Mind Medicine (MindMed) Inc
Image source: shutterstock

MNMD:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Mind Medicine (MindMed) Inc

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates.

Recent Business and Financial Updates

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.